secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001193125-24-155116
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences shareholders approve doubling authorized common stock to 300M shares
--------------------------------------------------------------------------------

- Amendment increases authorized common shares from 150M to 300M; total authorized shares from 160M to 310M.
- Outdated reverse stock split provisions deleted from the certificate of incorporation.
- All three director nominees elected; Andrew Robbins received 67.8M for, Peter Harwin received 51.7M for.
- Advisory vote on executive compensation passed with 69.6M for vs 6.7M against; future votes set for annual frequency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312524155116/0001193125-24-155116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312524155116/d805683d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-155116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer